GEN EdgeVol. 4, No. 1 Drug DiscoveryInfinimmune Raises 12-Million Seed Funding to Design Drugs Using Human-Sourced AntibodiesThe Bay Area startup is reinventing antibody discovery with an end-to-end, antigen-agnostic platform to deliver antibody drugs derived directly from the human immune systemJonathan D GrinsteinJonathan D GrinsteinSearch for more papers by this authorPublished Online:6 Dec 2022https://doi.org/10.1089/genedge.4.1.153AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 4Issue 1Jan 2022 Information© 2022 by GEN PublishingTo cite this article:Jonathan D Grinstein.Infinimmune Raises 12-Million Seed Funding to Design Drugs Using Human-Sourced Antibodies.GEN Edge.Jan 2022.911-914.http://doi.org/10.1089/genedge.4.1.153Published in Volume: 4 Issue 1: December 6, 2022PDF download